EXHIBIT 10.5
                                                                    ------------


Board of Directors of Doblique, Inc.
April 7, 2003

                                Jeffrey Katz C.A.

                               3737 The Boulevard
                                Westmount, Quebec
                                 Canada H3Y 1T3
                             Telephone 514-487-8966
                                Fax: 514-487-2138
                            E-Mail: jkatz@qc.aira.com



Dated as of April 7, 2003

To: The Board of Directors of Doblique, Inc.

Ladies and Gentlemen:

You have requested that Jeffrey Katz C.A.  ["Katz"]  provide you with an opinion
as to the  fairness,  from a  financial  point of view,  of the  transaction  in
connection  with the Stock Exchange  Agreement (the  "Agreement") as at April 7,
2003  (thereafter  "the valuation  date"),  by and among Inyx Pharma Limited,  a
company  registered in England and Wales ("Inyx Pharma"),  the parties listed in
Schedule 1 of the Agreement (each an "Inyx Pharma Shareholder," and collectively
the  "Inyx  Pharma   Shareholders")  and  Doblique,   Inc.  ("Doblique"  or  the
"Company"),  pursuant to which each Inyx  Pharma  Shareholder  shall  contribute
their  ordinary  shares in Inyx Pharma for shares of the Company's  common stock
(the "Company Shares").

Inyx  Pharma was prior to the  valuation  date  engaged in the  development  and
contract  manufacturing of specialized  pharmaceutical  aerosol products for the
treatment  of  respiratory,   allergy,  dermatological  and  topical  conditions
(thereafter "the Business").

Under the Agreement,  each Inyx Shareholder  shall assign,  transfer and deliver
their  respective  number of Inyx  shares  amounting  to 1  million  outstanding
ordinary  shares of Inyx Pharma,  in total,  to the Company,  who shall purchase
such number of Inyx Pharma  Shares  from each such Inyx Pharma  Shareholder.  In
consideration for the sale, assignment and transfer of the Inyx Pharma Shares to
the  Company  on the  Closing  Date,  the  Company  shall  issue  to  each  Inyx
Shareholder a proportionate  number of shares of Company Shares  amounting to 16
million common shares in total. The Company shall have no obligation to purchase
any  Inyx  Pharma  Shares  unless  all of  the  Inyx  Pharma  Shares  are  being
simultaneously purchased. As a result of the exchange transaction, Doblique will
own 100  percent of Inyx  Pharma's  issued  share  capital or 80 percent of Inyx
Pharma's authorized share capital,  as there are 1,250,000  authorized shares in
Inyx  Pharma,  250,000  shares of which have been  authorized  and reserved to a
convertible  note holder.

In arriving at the opinion set forth below,  Katz has  completed  the  following
tasks:


                                      -1-


<PAGE>

     1.   Reviewed   Inyx  Pharma's  2003  Business  Plan  as  prepared  by  its
          management.

     2.   Reviewed the financial  statements of Inyx Pharma and Doblique for the
          several years ended December 31, 2002, and various closing  documents,
          accounting and other records as of the valuation date.

     3.   Reviewed certain information,  including financial forecasts, relating
          to the  business,  earnings,  cash flows and  assets of the  Business,
          furnished to me by or on behalf on Inyx Pharma.

     4.   Conducted   discussions   with  members  of  the  management  of  Inyx
          concerning  the business and  prospects of the  Business;  discussions
          were also conducted with other industry participants.

     5.   Reviewed the report by Berkovits,  Lago and Company,  LLP on Doblique,
          Inc. and Inyx Pharma Limited reverse acquisition transaction

     6.   Compared  the  results  of  operations  of the  Business  with that of
          certain companies which I deemed relevant.

     7.   Conducted a financial review of the financial condition of Inyx Pharma
          with respect to its liquidity and capital position as of the valuation
          date.

     8.   Reviewed  the  Stock  Purchase  Agreement  and  ancillary   agreements
          thereto.

     9.   Performed  such other  analyses and  reviewed and analyzed  such other
          information as Katz deemed appropriate.

In rendering this opinion,  Katz did not assume responsibility for independently
verifying,  and did not independently verify, any financial or other information
concerning  Inyx  Pharma,   Doblique,  or  the  publicly  available  information
regarding other companies.

Katz has assumed that all such  financial and other  information is accurate and
complete.  Katz has further relied on the assurances of Inyx Pharma and Doblique
management  that they are not aware of any facts that would make such  financial
or other  information  inaccurate,  incomplete  or  misleading.  With respect to
forecasts and financial projections of Inyx Pharma provided by management,  Katz
has  assumed,  for the purpose of this  opinion,  that the  forecasts  have been
reasonably  prepared  on bases  reflecting  the  best  available  estimates  and
judgements  of  management  at the time of their  preparation  as to the  future
performance of the Business.  Katz has further assumed,  with your consent, that
any material  liabilities  (contingent  or  otherwise,  known or unknown) of the
Business are as set forth in the financial statements.

I have not been engaged to make, nor have I made, an  independent  evaluation or
appraisal of the assets or liabilities (contingent or otherwise) of the Business
nor have we been furnished with any such evaluation or appraisals except for the
Plant,  Machinery,  and  Equipment by Henry  Butcher  International  Inc. and by
Weatherall  Green & Smith  Northe  Ltd.  My opinion  is based  upon  regulatory,
economic,  market and monetary  conditions  existing on the date hereof.  I also
understand that each respective  party of the Agreement has sought its own legal
advice as to the  nature  of the  contemplated  transaction  and as to the legal
standing  of each  respective  entity,  as these are  outside of the scope of my
engagement.


                                      -2-
<PAGE>

This opinion has been prepared for your information in connection with the Stock
Exchange  Agreement  and  shall  not  be,  in  whole  or  in  part,  reproduced,
summarized,  described or referred to in any other opinion,  document or report,
or provided to any person or otherwise  made public without the prior consent of
Katz.  This  opinion is  delivered  as of the date  hereof  and I  disclaim  any
responsibility  to update this opinion at any time following the date hereof. On
the basis  of,  and  subject  to the  foregoing,  I am of the  opinion  that the
transaction  as  outlined  in  the  Stock  Exchange  Agreement  is  fair  to the
unaffiliated  shareholders  of the Company from a financial  point of view.  The
opinion  expressed above is based on a review of the  contemplated  transaction,
relevant  information  provided by the  respective  management  of each company,
industry and market  comparatives,  and is subject to the following  assumptions
and qualifications:

     >>   The Company is  economically  dependant  on a number of key  customers
          which include,  Merck Generics and Stiefel, which can together account
          for more than 50% of the Company's  revenues by 2005. I would strongly
          suggest a further diversification and growth of Inyx Pharma's customer
          base.

     >>   The Company should be seeking to locate its development  operations in
          locations  which promote tax incentives  for research and  development
          activities. One such example is the Province of Quebec in Canada which
          provides  a number of tax  incentives  that can  significantly  offset
          certain  development  costs.  Additionally,  there is also a number of
          multinational  pharmaceutical companies located in Quebec. The Company
          can significantly add value from the synergistic effects of locating a
          development operation amongst these other pharmaceutical companies.

     >>   In the coming months, the Company will require a significant injection
          of capital in order to provide for capital  equipment  and assets,  IT
          infrastructure  and regulatory  requirements and improvements.  I have
          not commented on the Company's financing plans.

     >>   One of the  areas  of  growth  that  the  Company  has not  adequately
          addressed in its  business  plan is growth by  acquisition  of similar
          pharmaceutical  businesses.  This is not the only  area of  growth  as
          there is unused  potential  and  capacity in existing  capital  assets
          owned by the Company.

     >>   I  have  not  seen a  clear  strategy  for  growth  through  strategic
          partnerships within the industry.  For example,  Inyx Pharma should be
          introduced  to such  companies as "Chaichen  Pharmaceuticals",  a bulk
          manufacturer of Taxol as a possible joint venture partner. These types
          of companies  can provide a number of  development  and  manufacturing
          opportunities.

Yours very truly,


/s/ Jeffrey Katz
----------------
Jeffrey Katz C.A.





                                       -3-